Modality
Radioligand
MOA
Menini
Target
DLL3
Pathway
Proteasome
MDS
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
~Dec 2018
→ ~Mar 2020
Phase 3
Jun 2020
→ Feb 2026
Phase 3Current
NCT04524918
2,794 pts·MDS
2020-06→2025-08·Not yet recruiting
NCT07325513
1,466 pts·MDS
2021-06→2026-02·Recruiting
NCT05500973
1,231 pts·MDS
2020-07→TBD·Completed
5,491 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-257mo agoPh3 Readout· MDS
2026-02-151mo agoPh3 Readout· MDS
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P3
Not yet…
P3
Complet…
P3
Recruit…
Catalysts
Ph3 Readout
2025-08-25 · 7mo ago
MDS
Ph3 Readout
2026-02-15 · 1mo ago
MDS
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04524918 | Phase 3 | MDS | Not yet recr... | 2794 | EFS |
| NCT07325513 | Phase 3 | MDS | Recruiting | 1466 | Biomarker |
| NCT05500973 | Phase 3 | MDS | Completed | 1231 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 |